Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma

References

• Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. May 19 2016;127(20):2375–7. doi:10.1182/blood-2016-01-643569.
   PubMed Web of Science ®Google Scholar
• Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 May;24(5):679–690. doi:10.1038/s41591-018-0016-8.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, Roulland S, Kasbekar M, Young RM, Shaffer AL, et al. Genetics and Pathogenesis of diffuse large B-Cell Lymphoma. N Engl J Med. Apr 12 2018;378(15):1396–1407. doi:10.1056/NEJMoa1801445.
   PubMed Web of Science ®Google Scholar
• Iacoboni G, Zucca E, Ghielmini M, Stathis A. Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review. Ann Oncol. May 1 2018;29(5):1120–1129. doi:10.1093/annonc/mdy113.
   PubMed Web of Science ®Google Scholar
• Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, et al. Polatuzumab vedotin in previously untreated diffuse large B-Cell lymphoma. N Engl J Med. Jan 27 2022;386(4):351–363. doi:10.1056/NEJMoa2115304.
   PubMed Web of Science ®Google Scholar
• Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–8. doi:10.1182/blood-2017-11-817775.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. Sep 20 2010;28(27):4184–90. doi:10.1200/jco.2010.28.1618.
   PubMed Web of Science ®Google Scholar
• Hutchings M. The evolving therapy of DLBCL: bispecific antibodies. Hematol Oncol. 2023 Jun;41(S1):107–111. doi:10.1002/hon.3154.
   PubMedGoogle Scholar
• Chow VA, Shadman M, Gopal AK. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma. Blood. Aug 23 2018;132(8):777–781. doi:10.1182/blood-2018-04-839217.
   PubMed Web of Science ®Google Scholar
• Rafiq S, Hackett CS, Brentjens RJ. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020 Mar;17(3):147–167. doi:10.1038/s41571-019-0297-y.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Herrera AF, Flowers CR, Kamdar MK, McMillan A, Hertzberg M, Assouline S, Kim TM, Kim WS, Ozcan M. et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-Cell Lymphoma. J Clin Oncol. Jan 10 2020;38(2):155–165. doi:10.1200/jco.19.00172.
   PubMed Web of Science ®Google Scholar
• Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):790–800. doi:10.1016/s1470-2045(21)00139-x.
   PubMed Web of Science ®Google Scholar
• Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S. et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol. 2020 Jul;7(7):511–22. doi:10.1016/s2352-3026(20)30120-4.
   PubMed Web of Science ®Google Scholar
• Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, et al. NCCN guidelines® insights: B-Cell Lymphomas, version 6.2023. J Natl Compr Canc Netw. 2023 Nov;21(11):1118–1131. doi:10.6004/jnccn.2023.0057.
   PubMedGoogle Scholar
• Dickinson MJ, Carlo-Stella C, Morschhauser F, Bachy E, Corradini P, Iacoboni G, Khan C, Wróbel T, Offner F, Trněný M, et al. Glofitamab for relapsed or refractory diffuse large B-Cell Lymphoma. N Engl J Med. Dec 15 2022;387(24):2220–2231. doi:10.1056/NEJMoa2206913.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman T, Gasiorowski R, Jurczak W, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-Cell–engaging antibody, in relapsed or refractory large B-Cell Lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. Apr 20 2023;41(12):2238–47. doi: 10.1200/jco.22.01725.
   PubMed Web of Science ®Google Scholar
• Bartlett NL, Assouline S, Giri P, Schuster SJ, Cheah CY, Matasar M, Gregory GP, Yoon DH, Shadman M, Fay K, et al. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2023;7(17):4926–4935. doi:10.1182/bloodadvances.2022009260.
   PubMed Web of Science ®Google Scholar
• Yang W, Agrawal N, Patel J, Edinger A, Osei E, Thut D, Powers J, Meyerson H. Diminished expression of CD19 in B-cell lymphomas. Cytometry B Clin Cytom. 2005 Jan;63(1):28–35. doi:10.1002/cyto.b.20030.
   PubMedGoogle Scholar
• Olejniczak SH, Stewart CC, Donohue K, Czuczman MS. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest. 2006;35(1):93–114. doi:10.1080/08820130500496878.
   PubMed Web of Science ®Google Scholar
• Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. Nov 29 2012;1(1):36. doi:10.1186/2162-3619-1-36.
   PubMedGoogle Scholar
• Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA. Mar 14 2006;103(11):4005–10. doi:10.1073/pnas.0508123103.
   PubMed Web of Science ®Google Scholar
• Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. Oct 1 2008;68(19):8049–57. doi:10.1158/0008-5472.Can-08-2268.
   PubMed Web of Science ®Google Scholar
• Salles G, Długosz-Danecka M, Ghesquières H, Jurczak W. Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. Expert Opin Biol Ther. 2021 Apr;21(4):455–463. doi:10.1080/14712598.2021.1884677.
   PubMed Web of Science ®Google Scholar
• Boxhammer R, Striebel F, Baumgartner R, Endell J. Expression of CD19 antigen on chronic lymphocytic leukemia cells after Tafasitamab (Anti-CD19) treatment: phase I trial data. Blood. 2019;134(Supplement_1):5061–5061. doi:10.1182/blood-2019-128613.
   Google Scholar
• Her JH, Pretscher D, Patra-Kneuer M, Schanzer J, Cho SY, Hwang YK, Hoeres T, Boxhammer R, Heitmueller C, Wilhelm M, et al. Tafasitamab mediates killing of B-cell non-Hodgkin’s lymphoma in combination with γδ T cell or allogeneic NK cell therapy. Cancer Immunol Immunother. 2022 Nov;71(11):2829–2836. doi:10.1007/s00262-022-03165-w.
   PubMed Web of Science ®Google Scholar
• Mangelberger D, Augsberger C, Landgraf K, Heitmüller C, Steidl S. Blockade of the CD47/SIRPα checkpoint potentiates the anti-tumor efficacy of Tafasitamab. Blood. 2020 [11/5/2020];136:11–12. doi:10.1182/blood-2020-139582.
   PubMed Web of Science ®Google Scholar
• Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM, Roda JM, Cheney C, Mo X, Lehman A, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody. Blood. 2010;115(6):1204–1213. doi:10.1182/blood-2009-06-229039.
   PubMed Web of Science ®Google Scholar
• Mougiakakos D, Voelkl S, Bach C, Stoll A, Bitterer K, Beier F, Endell J, Boxhammer R, Bittenbring JT, Mackensen A, et al. Mechanistic characterization of tafasitamab-mediated antibody-dependent cellular phagocytosis alone or in combination with lenalidomide. Blood. 2019;134(Supplement_1):4064–4064. doi:10.1182/blood-2019-124886.
   Google Scholar
• Woyach JA, Awan F, Flinn IW, Berdeja, J.G., Wiley, E., Mansoor, S., Huang, Y., Lozanski, G., Foster, P.A. and Byrd, J.C. et al. Dec 4 2014. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 124(24):3553–60. doi:10.1182/blood-2014-08-593269.
   PubMed Web of Science ®Google Scholar
• Belada D, Kopeckova K, Bergua Burgues JM, Stevens D, André M, Persona EP, Pichler P, Staber PB, Trneny M, Duell J, et al. Safety and efficacy of tafasitamab ± lenalidomide added to first-line R‑CHOP for DLBCL: phase 1b first-MIND study. Blood. 2023;142(16):1348–58. doi:10.1182/blood.2023020637.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Chiappella A. A new frontier for R-CHOP: is two better than one? Blood. 2023;142(16):1331–1332. doi:10.1182/blood.2023021521.
   PubMed Web of Science ®Google Scholar
• Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S, et al. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Ann Oncol. May 1 2018;29(5):1266–1272. doi:10.1093/annonc/mdy056.
   PubMed Web of Science ®Google Scholar
• Salles G, Duell J, González Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, André M, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol. 2020 Jul;21(7):978–988. doi:10.1016/s1470-2045(20)30225-4.
   PubMed Web of Science ®Google Scholar
• Duell J, Maddocks KJ, González-Barca E, Jurczak W, Liberati AM, De Vos S, Nagy Z, Obr A, Gaidano G, Abrisqueta P, et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica. 2021 Aug 19;106(9):2417–26. doi:10.3324/haematol.2021.279802.
   PubMed Web of Science ®Google Scholar
• Duell J, Abrisqueta P, Andre M, Gaidano G, Gonzales-Barca E, Jurczak W, Kalakonda N, Liberati AM, Maddocks KJ, Menne T, et al. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety in the phase II L-MIND study. Haematologica. 2023 Aug 31. doi:10.3324/haematol.2023.283480.
   Google Scholar
• Vitolo U, Nowakowski GS, Burke JM, Fox CP, Trneny M, Chiappella A, Waldron-Lynch M, Wagner S, Pachori A, Lenz G, et al. Frontmind: a phase III, multicenter, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-Cell Lymphoma. Blood. 2022;140(Supplement 1):6618–6620. doi:10.1182/blood-2022-155995.
   Google Scholar
• Zinzani PL, Rodgers T, Marino D, Frezzato M, Barbui AM, Castellino C, Meli E, Fowler NH, Salles G, Feinberg B, et al. RE-MIND: comparing tafasitamab + lenalidomide (L-MIND) with a real-world lenalidomide monotherapy cohort in relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res. Nov 15 2021;27(22):6124–6134. doi:10.1158/1078-0432.Ccr-21-1471.
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Trněný M, Davies A, Rule S, Linton KM, Wagner-Johnston N, Gascoyne RD, Slack GW, Brousset P, Eberhard DA, et al. A phase 2/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator’s choice in patients with relapsed or refractory diffuse large B-Cell Lymphoma. Clin Cancer Res. Aug 1 2017;23(15):4127–4137. doi:10.1158/1078-0432.Ccr-16-2818.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol. Oct 20 2008;26(30):4952–7. doi:10.1200/jco.2007.15.3429.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly H, Guo P, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011 Jul;22(7):1622–1627. doi:10.1093/annonc/mdq626.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Yoon DH, Mondello P, Joffe E, Peters A, Fleury I, Greil R, Ku M, Marks R, Kim K, et al. Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma. Ann Hematol. 2023 Sep;102(9):2643–2644. doi:10.1007/s00277-023-05321-3.
   PubMed Web of Science ®Google Scholar
• Qualls DA, Lambert N, Caimi PF, Merrill M, Pullarkat P, Godby RC, Bond DA, Wehmeyer GT, Romancik J, Amoozgar B, et al. Tafasitamab and lenalidomide in large B cell lymphoma: real-world outcomes in a multicenter retrospective study. Blood. 2023 Sep 22;142(26):2327–31. doi:10.1182/blood.2023021274.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, Huang Y, Lozanski G, Foster PA, Byrd JC. A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014;124(24):3553–60. doi:10.1182/blood-2014-08-593269.
   PubMed Web of Science ®Google Scholar